Showing 3521-3530 of 4262 results for "".
- Does Vitiligo-associated Autoimmunity Reduce Morbidity and Mortality?https://practicaldermatology.com/news/does-vitiligo-associated-autoimmunity-reduced-morbidity-and-mortality/2462014/Vitiligo-associated autoimmunity may play a role in reducing morbidity and mortality, according to a study in the Journal of Investigative Dermatology. When researchers investigated the mortality of patients with vitiligo in a population-base
- Severe Psoriasis Increases Risk for Heart Diseasehttps://practicaldermatology.com/news/severe-psoriasis-increases-risk-for-heart-disease/2462013/Researchers have found further evidence that patients with severe psoriasis are at higher risk for cardiovascular disease. In this study, a total of 503 patients with psoriasis, and without clinical cardiovascular disease, underwent transthoracic Doppler echocardiography to evaluate cor
- Beyond BSA: IPC, NPF Call Attention to Psoriasis Lesion Location on Q of Lhttps://practicaldermatology.com/news/beyond-bsa-ipc-npf-call-attention-to-psoriasis-lesion-location-on-q-of-l/2462007/The International Psoriasis Council (IPC) is partnering with the National Psoriasis Foundation (NPF) to call attention to the influence of psoriasis lesion locations on patients’ quality of life. The joint effort presents a study that delves into how psoriasis in specific areas
- AD News: Lebrikizumab Clears Hurdle in EUhttps://practicaldermatology.com/news/ad-news-lebrikizumab-clears-hurdle-in-eu/2462005/The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Almirall's EBGLYSS (lebrikizumab) for the treatment of adult and adolescent patients aged 12 and older with a body weight of at least 40 kg who have moderate
- One to Watch: Nektar Therapeutics' Rezpegaldesleukin Shows Promise in Phase 1b AD Studyhttps://practicaldermatology.com/news/one-to-watch-nektar-therapeutics-rezpegaldesleukin-shows-promise-in-phase-1b-ad-study/2462000/Nektar Therapeutics’ rezpegaldesleukin met several clinical efficacy endpoints with statistically significance, including Body Surface Area (BSA), Dermatology Life (DLQI), and Patient-Oriented Eczema Measure (POEM) in addition to reported efficacy for Eczema Area and Severity
- Cetaphil Takes on Aging Skin with New Skincare Linehttps://practicaldermatology.com/news/cetaphil-takes-on-aging-skin-with-new-skincare-line/2461995/Galderma is rolling out Cetaphil Healthy Renew, its first-ever healthy aging skincare line. "Aging skin is a particular point of frustration for my sensitive skin patients due to increased risks of irritation and an already compromised skin barrier,” says Cetaphil partn
- Study Sheds Light on Why Wounds Heal Poorly in People With Diabeteshttps://practicaldermatology.com/news/study-sheds-light-on-why-wounds-heal-poorly-in-people-with-diabetes/2461989/When exosomes are defective in diabetic patients, they can drive inflammation and impair healing of wounds, according to a new Nano Today study led by University of Pittsburgh and UPMC researchers
- FDA Clears Sofwave’s SUPERB Technology for Treating Acne Scarshttps://practicaldermatology.com/news/fda-clears-sofwaves-superb-technology-for-treating-acne-scars/2461969/The U.S. Food and Drug Administration (FDA) has cleared Sofwave’s SUPERB technology for treating acne scars. “Gaining FDA clearance to market SUPERB for the treatment of acne scarring not only paves the way to positively impact patients seeking improved appearances
- EMA Accepts LEO Pharma’s MAA for Delgocitinib Cream in Chronic Hand Eczemahttps://practicaldermatology.com/news/ema-accepts-leo-pharmas-maa-for-delgocitinib-cream-in-chronic-hand-eczema/2461942/The European Medicines Agency (EMA) has validated LEO Pharma’s marketing authorization application for delgocitinib cream, an investigational product and topical pan-Janus kinase (JAK) inhibitor for the treatment of adult patients with moderate to severe chronic hand eczema (CHE).
- Immunotherapy Drug Combo Helps Extend Progression-Free Survival in Metastatic Melanomahttps://practicaldermatology.com/news/immunotherapy-drug-combo-helps-extend-progression-free-survival-in-metastatic-melanoma/2461940/Combining two immune checkpoint inhibitors helps overcome resistance to prior PD-1 therapy in patients with metastatic melanoma, a new study shows. The combination of ipilimumab and nivolumab showed a longer progression-free survival, but also a greater overall response rate t